M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.

Abstract

BACKGROUND:

The M-VAC combination is very effective in bladder carcinoma, as are all four drugs, as single-agent, in advanced breast carcinoma.

PATIENTS AND METHODS:

M-VAC was given in 27 patients, 4 with locally advanced breast carcinoma, 3 with local recurrence and 20 with distant metastases. The median age was 51 (range 25; 70). Eleven of the 20 patients with metastatic disease has been previously treated with a different chemotherapy.

RESULTS:

15 of 26 evaluable patients responded, with 9 (35%) complete remissions and 6 partial responses. The overall response rate (CR plus PR) was 57% (95% confidence interval 38% to 76%). In patients with metastatic disease the median duration of response was 7 months (range 4+; 36+), median time to progression 5 months (range 1; 36+) and median duration of survival 17 months (range 1; 40+).

CONCLUSION:

The M-VAC combination is very effective in locally advanced, locally recurrent and metastatic breast carcinoma. Further trials are warranted to evaluate whether the activity of this combination is partially schedule-dependent.

• Authors: G Bisagni, G Cocconi, G Ceci, V De Lisi, B Di Blasio, R Lottici, R Passalacqua, C Finardi
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 5 Issue 1 Pg. 93-4 (Jan 1994) ISSN: 0923-7534 [Print] England
• PMID: 8172801 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Vinblastine
• Doxorubicin
• Cisplatin
• Methotrexate

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Cisplatin (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Methotrexate (therapeutic use)
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Recurrence, Local (drug therapy)
• Treatment Outcome
• Vinblastine (therapeutic use)